Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Jan 29, 2025 · Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares MRNA fell 2% in ...
Moderna's stock is falling. Goldman Sachs says it's no longer a buy.
Jan 29, 2025 · Goldman forecast RSV vaccine revenue of $1.5 billion, which is at the lowest end of the $1.5 billion to $2.5 billion range produced by Moderna. The Goldman team also says Moderna won't be cash ...
Moderna stock drops as Goldman Sachs cuts rating - Yahoo …
Jan 29, 2025 · Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative revisions to...
Moderna Stock Falls After Goldman Downgrade. Vaccine Sales …
Moderna stock was losing ground as investors appeared increasingly doubtful its vaccine sales will be able to lift the beaten-down share price. Goldman Sachs cut its recommendation on the stock to ...
Moderna down as Goldman Sachs downgrades on revenue …
Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook.
Moderna stock down as Goldman Sachs downgrades …
Jan 29, 2025 · Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue...
Moderna gets a downgrade from Goldman Sachs on vaccine …
Jan 29, 2025 · Goldman Sachs has turned more cautious on Moderna as the biotech struggles against strong competition from other vaccine makers. Analyst Salveen Richter downgraded …
Goldman Sachs Downgrades Moderna (WBAG:MRNA) - Nasdaq
Jan 29, 2025 · Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (WBAG:MRNA) from Buy to Neutral. What is the Fund Sentiment? There are 1,449 funds or institutions...
Moderna downgraded to Neutral from Buy at Goldman Sachs
Jan 29, 2025 · Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance represents the second in a series of negative revisions...
The Goldman Sachs Group Has Lowered Expectations for Moderna …
Jan 28, 2025 · Moderna (NASDAQ:MRNA - Get Free Report) had its price objective lowered by stock analysts at The Goldman Sachs Group from $112.00 to $99.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock.